Modern Mobility Aids returns 90M shares of MDRM

NewsGuard 100/100 Score
Mar 7 2012

Modern Mobility Aids, Inc. (the "Company"), headquartered in Nevada, USA, (OTC: MDRM) announces that its Chairman and CEO, Mohamed Karatella, today has returned 90 million shares of MDRM from his personal holdings back into the Company's treasury and in doing so has reduced his position in the Company from 130 million to 40 million shares.

Mr. Karatella has returned the shares, pro bono, for the purpose of decreasing the number of MDRM"s outstanding shares from 195.48 million to 105.48 million, thereby increasing share value and also to underline his confidence and commitment to the Company's recently announced new growth strategies.

Source:

Modern Mobility Aids, Inc.

Posted in: Business / Finance

Tags:

Comments (0)

Suggested Reading

COVID-19 pandemic reverses global life expectancy gains, reveals comprehensive study
Revolutionary CAR T-cell therapy shows promise in reversing age-related metabolic dysfunction
ChatGPT aids in discovering potential Alzheimer’s treatments through drug repurposing
Exploring the role of iodine in obesity, diabetes, and other metabolic conditions
Rethinking the germ theory: A balanced take on microbes and disease outcomes
Differences in leading causes of disease burden between males and females
Immunocompromised patients show prolonged SARS-CoV-2 infection and unique mutations
Higher cardiorespiratory fitness levels linked to dramatically lower mortality and disease risks, study finds

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
(Logout)
Post

Newsletters you may be interested in

See all Newsletters »

Terms

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

Provide Feedback

You might also like...
New machine learning model uses MRI scans to predict psychosis onset